Form 4: Avalo Therapeutics Director Michael Heffernan Granted 29,500 Stock Options

Avalo Therapeutics, Inc. Director Michael Thomas Heffernan was granted 29,500 stock options with an exercise price of $4.47, vesting on the first anniversary of the grant date.

Summary

• Michael Thomas Heffernan, a Director of Avalo Therapeutics, Inc. (AVTX), was granted 29,500 stock options.
• The stock options have an exercise price of $4.47 per share.
• The grant date for these options was June 17, 2025.
• The options are scheduled to vest 100% on the first anniversary of the grant date, which is June 17, 2026, contingent upon Mr. Heffernan's continued service.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Heffernan beneficially owns 29,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event, generally viewed as a positive for aligning management incentives with shareholder interests, without indicating any immediate negative or highly positive operational news.

Positives

• The grant of 29,500 stock options to Director Michael Thomas Heffernan aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.

Negatives

• NA

Risks

• NA

Future Outlook

The stock options are structured to vest 100% on the first anniversary of the grant date, contingent upon the director's continued service, indicating an incentive for long-term commitment and alignment with future company performance.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industry to align executive and director incentives with shareholder value and encourage long-term retention.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grant of 29,500 stock options to Michael Thomas Heffernan, a Director of Avalo Therapeutics, Inc., constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with long-term shareholder value creation, potentially leading to improved governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options are scheduled to vest on June 17, 2026, contingent on the director's continued service.

Key Dates

Keywords

Avalo Therapeutics, AVTX, stock options, director compensation, SEC Form 4, insider transaction, equity grant, corporate governance